Companies / AgomAb Therapeutics NV

AgomAb Therapeutics NV

Nasdaq: AGMBCIK 2020932ANTWERPEN

Ownership

34.2M shares outstanding
14.3%10%+ / strategic
Ownership
10%+ / strategic14.26%4,873,680
Institutions15.34%5,239,857
Public float70.40%24,053,631

% of common shares outstanding (single-class filing figure). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 11

View all โ†’
Insider% of sharesShares
โ€”โ€”
Borderias Andrea SaezChief Development Officer
โ€”โ€”
โ€”โ€”
Hammer OhadDirector
โ€”โ€”
โ€”โ€”
Kemula Pierre Thadee VictorChief Financial Officer
โ€”โ€”
Knotnerus Tim JasperCEOChief Executive Officer ยท Director
โ€”โ€”
Lefever EllenGeneral Counsel
โ€”โ€”
van der Horst Paul HenrykChief Business Officer
โ€”โ€”
โ€”โ€”

Institutional holders 9

View all โ†’

Activity

Jun 30, 2026View all โ†’
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ฮ”Position afterImpact
Q1 2026
as of
Sanofi
13F manager
NewCommon stock$29.19M+2.8M
2,783,096
8.15% of shares
medium
Q1 2026
as of
Federated Hermes Inc
13F manager
NewCommon stock$16.97M+1.6M
1,618,000
4.74% of shares
medium
Q1 2026
as of
Perceptive Advisors LLC
13F manager
NewCommon stock$6.29M+600K
600,000
1.76% of shares
medium
Q1 2026
as of
Millennium Management LLC
13F manager
NewCommon stock$999.0K+95K
95,233
0.28% of shares
low
Q1 2026
as of
Laurion Capital Management LP
13F manager
NewCommon stock$524.5K+50K
50,000
0.15% of shares
low
Q1 2026
as of
Sectoral Asset Management Inc
13F manager
NewCommon stock$477.3K+44K
43,500
0.13% of shares
low
Q2 2026
as of
Quadrature Capital Ltd
13F manager
NewCommon stock$265.6K+20K
20,461
0.06% of shares
low
Q1 2026
as of
D. E. Shaw & Co., Inc.
13F manager
NewCommon stock$160.8K+15K
15,326
0.04% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Fmr LLCPassive13Gโ€”4,873,680โ€”
SanofiPassive13Gโ€”โ€”โ€”

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AGMBโ€”โ€”00860C102โ€”